<DOC>
	<DOCNO>NCT02247973</DOCNO>
	<brief_summary>The study phase II trial design evaluate efficacy safety co-transplantation bone marrow derive mesenchymal stem cell related donor alternative donor transplantation severe aplastic anemia .</brief_summary>
	<brief_title>Mesenchymal Stem Cells Co-transplantation Alternative Donor Transplantation Severe Aplastic Anemia .</brief_title>
	<detailed_description>Aplastic anemia ( AA ) autoimmune hematologic stem cell disease mediate activated T-lymphocytes lead bone marrow dysfunction . In presence empty marrow , pancytopenia , transfusion dependence , severity disease base neutrophil ( PMN ) count : nonsevere AA ( nSAA ; PMN &gt; 0.5 × 109/L ) , severe AA ( SAA ; PMN 0.2- 0.5 × 109/L ) , severe AA ( vSAA ; PMN &lt; 0.2 × 109/L ) . Allogeneic BMT HLA-identical sibling donor matched-alternative donor treatment choice patient aplastic anaemia.Transplantation patient severe aplastic anaemia HLA identical sibling donor successful 75-90 % chance long term cure overall survival 65 % 73 % 5 year matched-alternative donor transplantation . However , two approach limited availability HLA-matched donor . Patients without HLA-identical sibling donor matched-alternative donor offer immunosuppressive treatment ( IST ) involve injection Anti-thymocyte globulin ( ATG ) combination cyclosporine ( CsA ) . The treatment response ATG best 60-80 % , 30 % -40 % patient relapse follow initial response treatment . Moreover , recent study show multivariate analysis response 6 month , young age , absolute reticulocyte count ( ARC ) absolute lymphocyte count ( ALC ) , correlate response ATG . Patients SAA vSAA , much low ARC ALC , poor response IST high risk die infection bleeding . Nowadays , advance transplant technology , HLA-mismatched related donor unrelated donor transplantation achieve good clinical result . Data XJ Huang indicate patient HLA-mismatched related donor achieve 100 % donor myeloid engraftment survival rate 64.6±12.4 % . Retrospectively analyzed result 154 patient acquire SAA receive BMT unrelated donor identify Japan Marrow Donor Program show probability OS 5 year 56 % ( 95 % confidence interval , 34 % -78 % ) . Compared malignant disease , mismatch related donor unrelated donor HSCT SAA involve distinct challenge mainly associate high graft failure high GVHD . So , find way promote implantation meanwhile prevent reduce GVHD , efficacy HLA-mismatched related donor transplantation improve . Mesenchymal stem cell ( MSCs ) multi-potent non-hematopoietic progenitor mainly find BM , cord blood , adipose tissue . MSCs attractive ease isolate expanded ex vivo , ability undergo multilineage differentiation , lack immunogenicity . These cell show provide support growth differentiation hematopoietic progenitor cell BM micro-environments . In additon , preliminary study show clinical effectiveness allogeneic MSC treatment refractory graft-versus-host disease improvement resolution severe aGVHD co-transplantation MSCs . Due property , MSCs become interesting candidate use cellular therapy consider `` theoretically perfect cell '' potential clinical use AA mismatch related donor transplantation .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>1 . In line 2009 Edition ( United Kingdom ) aplastic anemia diagnostic criterion SAA VSAA ; 2 . Age le 50 year old , willing transplant； 3 . No HLAidentical sibling donor； 4 . Have HLAmismatched related donor unrelated donor ( ≥5/10 HLA match loci related donor ; ≥8/10 HLA match loci unrelated donor ) 5 . No serious infection acute hemorrhage ; 6 . Cardiac ultrasound examination show left ventricular ejection fraction great 50 % ; 7 . Both transaminase serum creatinine level twice times upper limit normal value ( ULN ) ; 8 . No acute infectious disease ; 9 . Ability understand willingness sign write informed consent document . 10 . ECOG score 02 point . 1 . Patients severe infection active bleeding ; 2 . With severe cardiac insufficiency , leave ventricular ejection fraction &lt; 50 % ; 3 . With severe liver dysfunction , liver function ( ALT TBIL ) high ULN 3 time ; 4 . With severe renal insufficiency , renal function ( Cr ) twice high ULN ; 24hour urine creatinine clearance rate ( Ccr ) low 50ml/min ; 5 . Active tuberculosis , severe acute hepatitis infectious disease active period ; 6 . ECOG score 3 point ; 7 . Accompanied malignant tumor clonal disease ; 8 . Poor compliance researcher consider unsuitable MSC infusion .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>